LI-COR (PRIVATE.LICOR)

Overall impact
C (58)

Commentary

LI-COR is an average overall performer. With a 'C' rating of 57.7 for overall impact (58th percentile compared to all companies), LI-COR ranks 69th out of 103 industry peers, behind Waters, MyMD Pharmaceuticals, Alphatec and 65 others, and ahead of Envista Holdings, Sientra, Mesa Laboratories and 31 others. On top material causes for LI-COR's industry (Healthcare Equipment), LI-COR performs well in Improved Mental Health (83.6 score), Child and Maternal Health (95.4), Technology Innovation (94.8) and 1 other cause where it received an 'A' score and performs poorly in Humane Treatment of Animals (31.9 score), Sustainable Use of Natural Resources (31.5), Sanitation Access (35.1) and 2 other causes where it received a 'D' or 'F' score.
Impact
Cause PRIVATE.LICOR
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
1971
Employees
400
Sector
Health Care
Industry
Health Care Equipment & Supplies
Sub-industry
Health Care Supplies
SASB industry
Medical Equipment & Supplies
Headquarters
Nebraska, United States
Share classes
PRIVATE.LICOR
Description
Developer of environmental and biotech products designed for targeted therapeutics research, protein studies and microbial-related drug development. The company offers imaging systems, studio software, template designer and gas analyzers, enabling scientists and researchers to address important biological and environmental challenges.
Material causes
Ethos considers the following causes material for LI-COR, based on its industry sub-industry Health Care Supplies. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.